PLEASE JOIN US FOR AN EDUCATIONAL WEBCAST

Real world management of haemophilia with Idelvion® and Afstyla®

Registered but not currently available in Australia and New Zealand, Idelvion (rIX-FP; albumin fusion) and Afstyla (rVIII-SingleChain) have now been used for many years in routine clinical practice across Europe and USA. Both products have become key to haemophilia management in countries where they are available.

Real world evidence studies in a number of countries have confirmed the clinical efficacy and utility of Idelvion and Afstyla. Join this **interactive webinar** to learn the latest on these studies from an international expert who prescribes these treatments on a daily basis, and to hear from a leading Australian clinician with trials experience.

DATE:
WEDNESDAY
25 SEP 2024

TIME:
8:00 PM

PRESENTERS:

Prof. Johannes Oldenburg

Professor of Transfusion Medicine

Prof. Johannes Oldenburg is Director of the Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Germany.

He is author of over 600 publications, recipient of numerous scientific awards, journal editor & reviewer, and is active as a member of various national and international committees.

Dr. Julie Curtin

Paediatric Haematologist

Dr. Julie Curtin is a paediatric haematologist and Director of the Haemophilia Treatment Centre at The Children's Hospital, Westmead in Sydney, Australia.

She participated in clinical trials with Idelvion, making her one of the few people in Australia and New Zealand with hands-on experience of rIX-FP.

REGISTER HERE:
cslbehring.medevents.com.au

ACCESS CODE:
CSL259W

CSL Behring

PLEASE JOIN US FOR AN EDUCATIONAL WEBCAST

AGENDA:

7:30 pm	Online meeting room opens
8:00 pm	Welcome and Introduction
8:05 pm	Real world management experience
8:40 pm	ANZ insights
8:50 pm	Q&A
9:00 pm	Meeting Close

For further information, please contact:

Andrew Stork +61 437 126 545 Andrew.Stork@cslbehring.com.au

Before prescribing, please review full data sheet available from CSL Behring Medical Information: medicalinformation@cslbehring.com.au or call 0800 640 677

AFSTYLA® (lonoctocog alfa) 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU, 2500 IU, 3000 IU, powder for injection with diluent. **Indications:** adult and paediatric patients with haemophilia A (congenital FVIII deficiency) for control and prevention of bleeding episodes, routine prophylaxis to prevent or reduce the frequency of bleeding episodes, perioperative management (surgical prophylaxis). Not indicated for the treatment of von Willebrand disease. **Precautions:** Allergic type hypersensitivity reactions, including anaphylaxis. Immediately discontinue and initiate treatment if hypersensitivity reactions occur. Pre-medication with antihistamines may be considered. Formation of neutralising antibodies (inhibitors) to FVIII has been reported and patients should be monitored for inhibitor development. Monitor FVIII plasma activity using chromogenic assay or one-stage clotting assay. If a central venous access device is required, consider risk of complications including local infections, bacteraemia and catheter site thrombosis. **Contraindications:** in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis to AFSTYLA, any of the excipients, or hamster proteins. **Adverse events:** hypersensitivity, dizziness, paraesthesia, rash, pyrexia. FVIII inhibition in previously untreated patients. **Dosage and administration:** Intravenous use after reconstitution. Initiate under the supervision of a physician experienced in haemophilia A. Monitor patient for immediate reaction. Home treatment at physician's discretion. The dose and duration of the treatment depend on the severity of the FVIII deficiency, the location and extent of the bleeding, and the patient's clinical condition. Refer to Data Sheet for guidance on dosing on demand, for prophylaxis and paediatrics. Record batch number of product administered.

Classification: B02BD04 (antihaemorrhagics, blood coagulation factor VIII)
AFSTYLA® is not listed on the Pharmaceutical Schedule.

IDELVION® (albutrepenonacog alfa) 250 IU, 500 IU, 1000 IU, 2000 IU, 3500 IU, powder for injection with diluent. **Indications:** patients with haemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes, control and prevention of bleeding episodes, or bleeding in the perioperative setting. **Precautions:** Allergic type hypersensitivity reactions possible. Immediately discontinue and initiate treatment if hypersensitivity symptoms occur. Initial administrations should be performed under medical observation. Risk of thrombotic complications. Surveillance for signs of thrombotic and consumptive coagulopathy should be initiated with appropriate biological testing when administering to patients with liver disease, post-operatively, new-born infants, or to patients at risk of thrombotic phenomena or disseminated intravascular coagulation (DIC). Formation of neutralising antibodies (inhibitors) to FIX has been reported. Monitor patients for inhibitor development. Monitor plasma FIX activity by performing the one-stage clotting assay. **Contraindications:** in patients with known hypersensitivity to IDELVION, any of the excipients, or hamster proteins. **Adverse events:** headache, dizziness, injection site reactions. **Dosage and administration:** Intravenous use after reconstitution. Monitor patient for immediate reaction. Refer to Data Sheet for guidance on dosing on demand, for prophylaxis, in perioperative setting, and paediatrics. Record batch number of product administered.

Classification: B02BD04 (antihaemorrhagics, blood coagulation factor IX)
IDELVION® is not listed on the Pharmaceutical Schedule.

By registering for this event, you agree that you are a healthcare professional registered to practice in New Zealand and consent to your data being collected in accordance with the CSL Behring Privacy Policy (www.csl.com/privacy-policy) and agree to receiving communications from CSL Behring in relation to this event. As CSL Behring abides by the Medicines New Zealand Codes of Conduct, only invitees may attend this event.

Opt-out Statement: If you do not wish to receive further information about CSL Behring services, please email customerservice@cslberhing.com.au and provide your name and contact details.

Privacy Notice: Your personal information will be used by CSL and its group legal entities (full list available here https://privacy.csl.com/csl-group-legal-entities) ('we', 'us', 'CSL') in connection with registering your attendance at this event and sending you related communications. CSL may also use your personal information to email you about products or services, as elected by you. If your personal information is not provided it may not be possible to register you for the event. We may disclose personal information to third parties including Thrivase strictly for the purpose of hosting the event, in which case we will take appropriate measures to ensure your information is maintained securely and in confidence. Some of these entities (including CSL group entities) may be located overseas. The countries in which recipients may be located include (but are not limited to) the United States, Switzerland and countries within the European Union. Further information about how CSL may use your personal information, including how you can make an enquiry or exercise any rights in relation to your personal information is set out in our Privacy Policy available at http://www.csl.com/privacy-policy.

This session is proudly presented by

CSL Behring

CSL Behring (NZ) Limited, P O Box 62590, Greenlane, Auckland 1546, New Zealand.
Idelvion and Afstyla are registered trademarks of CSL Limited or it's affiliated companies.
Medical Information: 0800 640 677 (New Zealand). Date of preparation: September 2024. AU-COA-0045